TD Cowen lowered the firm’s price target on GoodRx (GDRX) to $3 from $6 and keeps a Buy rating on the shares. The firm said they beat 4Q revenues/EBITDA, but investors will likely be concerned on 2026 guidance, particularly headwinds from reduced economics with PTR partners.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $2 from $4 at UBS
- Balancing Near-Term Headwinds and Long-Term Growth: Justifying a Buy/High-Risk Rating on Pharma Direct-Led Upside
- GoodRx price target lowered to $3 from $4 at Mizuho
- GoodRx downgraded to Neutral from Overweight at JPMorgan
- GoodRx downgraded to Neutral at JPMorgan on ‘murky’ outlook